BR112016010409A8 - composto, composição farmacêutica, combinação, e, uso de um composto e de uma combinação - Google Patents

composto, composição farmacêutica, combinação, e, uso de um composto e de uma combinação Download PDF

Info

Publication number
BR112016010409A8
BR112016010409A8 BR112016010409A BR112016010409A BR112016010409A8 BR 112016010409 A8 BR112016010409 A8 BR 112016010409A8 BR 112016010409 A BR112016010409 A BR 112016010409A BR 112016010409 A BR112016010409 A BR 112016010409A BR 112016010409 A8 BR112016010409 A8 BR 112016010409A8
Authority
BR
Brazil
Prior art keywords
compound
combination
pharmaceutical composition
compositions
combinations
Prior art date
Application number
BR112016010409A
Other languages
English (en)
Inventor
Dominic Sanderson Francis
Mary Vallance Sarah
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112016010409A8 publication Critical patent/BR112016010409A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

um composto que é o sal bromidrato de n-{4-cloro-2-hidroxi-3-[(3s)-3-piperidinilsulfonil]fenil}-n?-(3-fluoro-2-metilfenil)ureia, composições, combinações e medicamentos contendo referidos compostos e processos para sua preparação. a invenção também se refere ao uso de referidos compostos, combinações, composições e medicamentos.
BR112016010409A 2013-11-13 2014-11-11 composto, composição farmacêutica, combinação, e, uso de um composto e de uma combinação BR112016010409A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1320021.7A GB201320021D0 (en) 2013-11-13 2013-11-13 Novel Compounds
PCT/EP2014/074222 WO2015071235A1 (en) 2013-11-13 2014-11-11 Hydrobromide salt ofn-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea

Publications (1)

Publication Number Publication Date
BR112016010409A8 true BR112016010409A8 (pt) 2020-04-22

Family

ID=49818555

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016010409A BR112016010409A8 (pt) 2013-11-13 2014-11-11 composto, composição farmacêutica, combinação, e, uso de um composto e de uma combinação

Country Status (23)

Country Link
US (3) US9809540B2 (pt)
EP (1) EP3068763B1 (pt)
JP (1) JP6401265B2 (pt)
KR (1) KR20160083950A (pt)
CN (1) CN105683162A (pt)
AU (1) AU2014350334B2 (pt)
BR (1) BR112016010409A8 (pt)
CA (1) CA2929907A1 (pt)
CY (1) CY1121581T1 (pt)
DK (1) DK3068763T3 (pt)
ES (1) ES2714721T3 (pt)
GB (1) GB201320021D0 (pt)
HR (1) HRP20190449T1 (pt)
HU (1) HUE041873T2 (pt)
LT (1) LT3068763T (pt)
ME (1) ME03328B (pt)
PL (1) PL3068763T3 (pt)
PT (1) PT3068763T (pt)
RS (1) RS58382B1 (pt)
RU (1) RU2685408C1 (pt)
SI (1) SI3068763T1 (pt)
TR (1) TR201902981T4 (pt)
WO (1) WO2015071235A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170100385A1 (en) * 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
CN108289840A (zh) * 2015-11-30 2018-07-17 葛兰素史密斯克莱知识产权（第2号）有限公司 用于静脉内注射Danirixin的制剂
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090093451A1 (en) * 2006-04-21 2009-04-09 Smithkline Beecham Corporation IL-8 Receptor Antagonists

Also Published As

Publication number Publication date
EP3068763A1 (en) 2016-09-21
AU2014350334B2 (en) 2017-08-10
CY1121581T1 (el) 2020-05-29
TR201902981T4 (tr) 2019-03-21
ES2714721T3 (es) 2019-05-29
AU2014350334A1 (en) 2016-06-02
WO2015071235A1 (en) 2015-05-21
LT3068763T (lt) 2019-03-12
RU2016116955A (ru) 2017-12-19
EP3068763B1 (en) 2018-12-19
US10604485B2 (en) 2020-03-31
HUE041873T2 (hu) 2019-05-28
US9809540B2 (en) 2017-11-07
CN105683162A (zh) 2016-06-15
KR20160083950A (ko) 2016-07-12
ME03328B (me) 2019-10-20
US20180079722A1 (en) 2018-03-22
RS58382B1 (sr) 2019-04-30
JP6401265B2 (ja) 2018-10-10
PT3068763T (pt) 2019-03-20
HRP20190449T1 (hr) 2019-04-19
SI3068763T1 (sl) 2019-04-30
CA2929907A1 (en) 2015-05-21
JP2016537344A (ja) 2016-12-01
US20160264525A1 (en) 2016-09-15
US20190112269A1 (en) 2019-04-18
PL3068763T3 (pl) 2019-05-31
RU2685408C1 (ru) 2019-04-18
GB201320021D0 (en) 2013-12-25
DK3068763T3 (en) 2019-03-18

Similar Documents

Publication Publication Date Title
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
GT201600085A (es) Composiciones y métodos para modular los receptores x farnesoides
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
BR112014029706A8 (pt) Composto, composição farmacêutica, e, uso de um composto
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112015007310A2 (pt) compostos, composição farmacêutica, uso de um composto de fórmula (i) e uso de uma composição farmacêutica
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
BR112015031878A2 (pt) composição farmacêutica
BR112018072755A2 (pt) composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica
ECSP15000868A (es) Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
BR112015022092A2 (pt) derivado de di-hidropiridazina-3,5-diona
BR112018002115A2 (pt) benzamidas aneladas
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
CR20150322A (es) Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2696 DE 06-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.